
Opinion|Videos|December 16, 2025
Dose Reducing and Sequencing Therapies in Desmoid Tumors
Experts discuss dose reduction strategies and emerging therapies for desmoid tumors, emphasizing patient monitoring and quality of life improvements.
Advertisement
Episodes in this series

Panelists discuss the questions below in this video.
- When is it appropriate to dose reduce with nirogacestat and how can this ensure the desired clinical outcomes are met?
- How are you sequencing therapies in your institution?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
FDA to Accept Deidentified Real-World Evidence for Select Medical Device Applications
2
COVID-19 Vaccination in Pregnant Patients Reduces Hospitalization, Preterm Birth Across Variants
3
FDA Approves Fam-Trastuzumab Deruxtecan-Nxki for Metastatic HER2-Positive Breast Cancer
4
Pembrolizumab Achieved pCR in Patient With Recurrent DDLPS
5









































